Table 1. Clinical features of P2RY8low and P2RY8hi patients.
| Features | SLE patients without P2RY8 variants | Patients with P2RY8 variants | ||||
|---|---|---|---|---|---|---|
| P2RY8low (n = 22) | P2RY8hi (n = 31) | P value | +/L257 (n = 1) | +/N97K (n = 1) | +/E323G (n = 6) | |
| Diagnosis | SLE | SLE | SLE | APS | SLE | |
| Sex, female | 100% (22/22) | 100% (31/31) | N/A | 100% (1/1) | 0% (0/1) | 83% (5/6) |
| Age at onset (yr) | 24.41 ± 9.12 | 23.80 ± 9.82 | 0.8754 | 13 | 45 | 28.83 ± 18.99 |
| SLEDAI | 10.82 ± 5.41 | 10.31 ± 4.12 | 0.7354 | 12 | N/A | 7.67 ± 3.50 |
| Alopecia | 32% (7/22) | 29% (9/31) | 0.7703 | 0% (0/1) | 0% (0/1) | 17% (1/6) |
| Arthritis | 64% (14/22) | 45% (14/31) | 0.1843 | 100% (1/1) | 0% (0/1) | 50% (3/6) |
| Serositis | 5% (1/22) | 0% (0/31) | 0.2308 | 0% (0/1) | 0% (0/1) | 17% (1/6) |
| Leukopenia | 23% (5/22) | 39% (12/31) | 0.2193 | 0% (0/1) | 0% (0/1) | 17% (1/6) |
| Lymphopenia | 50% (11/22) | 33% (10/30) | 0.2262 | 0% (0/1) | 100% (1/1) | 17% (1/6) |
| Renal | 64% (14/22) | 32% (10/31) | 0.0237 | 100% (1/1) | 0% (0/1) | 33% (2/6) |
| ANA | 100% (21/21) | 100% (28/28) | N/A | 100% (1/1) | 100% (1/1) | 100% (6/6) |
| Anti-dsDNA | 68% (15/22) | 45% (14/31) | 0.0971 | 100% (1/1) | 0% (0/1) | 83% (5/6) |
| Anti-SM | 32% (7/22) | 13% (4/30) | 0.1069 | 100% (1/1) | 0% (0/1) | 33% (2/6) |
| Anti-RNP | 40% (8/20) | 26% (7/27) | 0.3061 | 100% (1/1) | 0% (0/1) | 33% (2/6) |
| Anti-SSA | 50% (11/22) | 52% (16/31) | 0.9079 | 100% (1/1) | 0% (0/1) | 50% (3/6) |
| Anti-SSB | 14% (3/22) | 13% (4/31) | 0.9381 | 0% (0/1) | 0% (0/1) | 17% (1/6) |
| Cardiolipin antibodies | 0% (0/22) | 3% (1/29) | 0.3790 | 0% (0/1) | 100% (1/1) | 17% (1/6) |
| β-2 glycoprotein I antibodies | 8% (1/12) | 16% (3/19) | 0.5464 | 0% (0/1) | 100% (1/1) | 25% (1/4) |
| Consumed C3 | 86% (18/21) | 90% (27/30) | 0.6401 | 100% (1/1) | 0% (0/1) | 83% (5/6) |
| Consumed C4 | 81% (17/21) | 63% (19/30) | 0.1741 | 100% (1/1) | 0% (0/1) | 83% (5/6) |
| Medication | MP, HCQ, MMF | Warfarin | ||||
| MP | 14% (3/21) | 27% (8/30) | 0.2901 | 100% (1/1) | 0% (0/1) | 33% (2/6) |
| PDN | 29% (6/21) | 27% (8/30) | 0.8808 | 0% (0/1) | 0% (0/1) | 67% (4/6) |
| HCQ | 19% (4/21) | 17% (5/30) | 0.8263 | 100% (1/1) | 0% (0/1) | 33% (2/6) |
| MMF | 9.5% (2/21) | 13% (4/30) | 0.6777 | 100% (1/1) | 0% (0/1) | 33% (2/6) |
P2RY8low, geometric mean (gFMI) in B cells < 16,864 (mean value of P2RY8 gMFI in B cells from healthy control donors); P2RY8hi, P2RY8 gMFI in B cells > 16,864. Data were presented in the form of mean ± SD or % (n/total). P value was determined by Mann-Whitney test or by χ2 test. A P value <0.05 is considered statistically significant and is bolded. C3, complement C3; C4, complement C4; MP, methylprednisolone; N/A, not applicable; PDN, prednisone; RNP, ribonucleoprotein; SS, Sjogren syndrome.